Platelet activation is less enhanced in the new balloon expandable edwards sapien 3 valve compared to its predecessor model (Edwards Sapien XT)

Thrombosis and Haemostasis

Volumn 115, Issue 1, 2016, Pages 109-116

  Fateh Moghadam, Suzanne ^a   Voesch, Sabrina ^a   Htun, Patrik ^a   Jorbenadze, Rezo ^a   Geisler, Tobias ^a   Gawaz, Meinrad ^a   Bocksch, Wolfgang ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

DAPT; Edwards Sapien 3 valve; Edwards Sapien XT; Platelet activation; Residual aortic regurgitation; TAVR

Indexed keywords

PADGEM PROTEIN; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; SELP PROTEIN, HUMAN;

AGED; AORTA STENOSIS; AORTA VALVE REGURGITATION; ARTICLE; COHORT ANALYSIS; EDWARDS SAPIEN 3 VALVE; EDWARDS SAPIEN XT VALVE; ELECTROCARDIOGRAPHY; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; OUTCOME ASSESSMENT; PERCUTANEOUS AORTIC VALVE; PRIORITY JOURNAL; THORAX RADIOGRAPHY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; TRANSCATHETER AORTIC VALVE IMPLANTATION; TRANSTHORACIC ECHOCARDIOGRAPHY; VERY ELDERLY; ADVERSE EFFECTS; AORTA VALVE; AORTIC VALVE INSUFFICIENCY; AORTIC VALVE STENOSIS; BLOOD; BLOOD CLOTTING PARAMETERS; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DEVICES; DRUG EFFECTS; GERMANY; HEART CATHETERIZATION; HEART VALVE PROSTHESIS; HEART VALVE REPLACEMENT; PROSPECTIVE STUDY; PROSTHESIS DESIGN; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TRANSLUMINAL VALVULOPLASTY; TREATMENT OUTCOME;

AGED, 80 AND OVER; AORTIC VALVE; AORTIC VALVE INSUFFICIENCY; AORTIC VALVE STENOSIS; BALLOON VALVULOPLASTY; BIOMARKERS; CARDIAC CATHETERIZATION; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HEART VALVE PROSTHESIS; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET COUNT; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84951294355     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-03-0267     Document Type: Article

References (28)

1. Kodali SK, Wiliams MR, Smith CR, et al. for the PARTNER Trial Investigators. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012; 366: 1686-1695.
2. Gilard M, Eltchaninoff H, Iung B, et al. for the FRANCE 2 Investigators. Registry of transcatheter aortic-valve implantation in high-risk patients. N Engl J Med 2012; 366: 1705-1715.
3. Vahanian A, Alfieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease. Eur Heart J 2012; 33: 2451-2496.
4. Webb JG, Rodés-Cabau J, Fremes S, et al. Transcatheter aortic valve implantation : a Canadian Cardiovascuar Society position statement. Can J Cardiol 2012; 28: 520-528.
5. Grube E, Laborde JC, Gerckens U, et al. Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. Circulation 2006; 114: 1616-1624.
6. Gallet R, Seemann A, Yamamoto M, et al. Effect of transcatheter (via femoral artery) aortic valve implantation on the platelet count and its consequences. Am J Cardiol 2013; 111: 1619-1624.
7. Jilaihawi H, Doctor N, Chakravarty T, et al. Major thrombocytopenia after balloon-expandable transcatheter aortic valve replacement: prognostic implica-tions and comparison to surgical aortic valve replacement. Catheter Cardiovasc Intervent 2015; 85: 130-137.
8. Matthai WH Jr. Thrombocytopenia in cardiovascular patients: diagnosis and management. Chest 2005; 127: 46S-52S.
9. Lee DH, Buth KJ, Martin BJ, et al. Frail patients are at increased risk for mortality and prolonged institutional care after cardiac surgery. Circulation 2010; 121: 973-978.
10. Webb JG, Chandavimol M, Thompson CR, et al. Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation 2006; 113: 842-850.
11. Cribier A, Eltchaninoff H, Tron C, et al. Treatment of calcific aortic stenosis with the percutaneous heart valve: mid-term follow-up from the initial feasibility studies: the French experience. J Am Coll Cardiol 2006; 47: 1214-1223.
12. Cribier A, Litzler PY, Eltchaninoff H, et al. Technique of transcatheter aortic valve implantation with the Edwards-Sapien heart valve using the transfemoral approach. Herz 2009; 34: 347-356.
13. De Jaegere P, van Dijk LC, Laborde JC, et al. True percutaneous implantation of the CoreValve aortic valve prosthesis by the combined use of ultrasound guided vascular access, Prostar ® XL, and the Tandem Heart ®. Eurointervention 2007; 2: 500-505.
14. Sharp AS, Michev I, Maisano F, et al. A new technique for vascular access management in transcatheter aortic valve implantation. Catheter Cardiovasc Interv 2010; 75: 784-793.
15. Tóth O, Calatzis A, Penz S, et al. Multiple electrode aggregometry : a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96: 781-788.
16. Sibbing D, Braun S, Jawansky S, et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb Haemost 2008; 99: 121-126.
17. Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behaviour in whole blood. J Pharmacol Methods 1980; 3: 135-158.
18. Gawaz M, Reininger A, Neumann FJ. Platelet function and platelet-leucocyte adhesion in symptomatic coronary heart disease: effects of intravenous magnesium. Thromb Res 1996:83: 341-349
19. Gawaz M, Neumann FJ, Schömig A. Evaluation of platelet membrane glycoproteins in coronary artery disease: consequences for diagnosis and therapy. Circulation 1999; 99: E1-E11.
20. Dvir D, Généreux P, Barbash IM, et al. Acquired thrombocytopenia after transcatheter aortic valve replacement: clinical correlates and association with outcomes. Eur Heart J 2014; 38: 2663-2671.
21. Webb J, Gerosa G, Lefèvre T, et al. Multicenter evaluation of a next-generation balloon-expandable transcatheter aortic valve. J Am Coll Cardiol 2014; 64: 2235-2243.
22. Polzin A, Schleicher M, Seidel H, et al. High on-treatment platelet reactivity intranscatheter aortic valve implantation patients. Eur J Pharmacol 2015; 751: 24-27.
23. Tantry US, Bonello L, Aradi D et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62: 2261-2273.
24. Lordkipanidzé M, Pharand Ch, Nguyen TA et al. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 2008; 29: 2877-2885.
25. Ussia GP, Scarabelli M, Mulè M, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2011; 108: 1772-1776.
26. Stabile E, Pucciarelli A, Cota L, et al. SAT-TAVI (single antiplatelet therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. Int J Cardiol 2014; 174: 624-627.
27. Aspirin versus Aspirin + Clopidogrel following transcatheter aortic valve implantation: The ARTE Trial. 2012. Available at:http://clinicaltrials.gov/ct2/show/nct01559298?termnct01559298&rank=1. Accessed May 30, 2012
28. Rodés-Cabau J, Dauermann HL, Cohen MG, et al. Antithrombotic treatment in transcatheter aortic valve implantation. Insights for cerebral and bleeding events. J Am Coll Cardiol 2013; 62: 2349-2359.